Oxiglutatione
CAS 27025-41-8
Oxiglutatione (CAS 27025-41-8) is a Phase 4 pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 34850.97777777778 nM | 6 | - |
| - | IC50 | 100000 nM | 2 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| glutathione-disulfide reductase GSR |
Inhibition | - | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Oxiglutatione used for in pharmaceutical contexts?
Oxiglutatione (CAS 27025-41-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Oxiglutatione?
No adverse-event association or SIDER side-effect rows are rendered for Oxiglutatione in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Oxiglutatione also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for OXIDIZED GLUTATHIONE with EU status "permitted".
What clinical phase is Oxiglutatione in?
Oxiglutatione is rendered with ChEMBL max phase 4 (approved).